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Abstract
Clostridium difficile infection (CDI) has become a serious medical and epidemiological problem, especially in well developed 
countries. There has been evident increase in incidence and severity of CDI. Prevention, proper diagnosis and effective treatment 
are necessary to reduce the risk for the patients, deplete the spreading of infection and diminish the probability of recurrent 
infection. Antibiotics are the fundamental treatment of CDI. In patients who had recurrent CDI fecal microbiota transplantation 
seems to be promising and efficient strategy. These guidelines systematize existing data and include recent changes implement-
ed in the management of CDI.
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1. Guideline methodology
The clinical practice guidelines for management of 
Clostridium difficile infections in adults were developed 
by the task force of the Board of the Polish Gastroenter-
ology Society. This document summarises recommenda-
tions for improved diagnosis and treatment of C. difficile 
infections (CDI) in adults. The definition of CDI includes 
symptoms, usually diarrhoea, and a positive stool test 
for C. difficile toxin, or detection of a toxin-producing 
C. difficile strain, or a typical endoscopic image, or pa-
thology study confirming pseudomembranous colitis. In 
addition, for proper diagnosis, treatment, patient care, 
and prevention, the guidelines include recommended 
methods of infection control, patient management, and 
infection prevention. The panel includes systematic rat-
ing of strength and quality of evidence in compliance 
with the GRADE system (evaluation of rating, recommen-
dation development, and assessment) (Tables I and II). 
A detailed description of the methods, background, and 
summary of evidence in support of each recommenda-
tion is provided in the full text of the guidelines.
1.1. Scope and aims of the guidelines
1.1.1. Aims
Clostridium difficile is still the most common cause 
of healthcare-associated diarrhoea. It became the most 
important pathogen in hospitalised patients for several 
reasons. The main purpose of the guidelines is to identi-
fy the best methods for diagnosis and management, as 
well as the most effective, sufficient, and safe treatment 
regimens for CDI patients. We expect that application of 
the guidelines will translate into greater disease aware-
ness, help reduce costs of differential diagnosis, and will 
contribute to appropriate CDI management.
1.1.2.  Health problems discussed in the guidelines
The following CDI-associated health questions are 
covered in the guidelines:
1. What is the aetiology of CDI?
2.  What has been the epidemiological situation of CDI 
in recent years?
3.  What are the clinical symptoms of CDI?
4.  What are the diagnostic criteria for CDI?
5.  Which clinical tools should be considered in differen-
tia diagnosis?
6.  What is the proper management of CDI (including ther-
apy, patient monitoring, isolation, and supportive care)?
1.1.3. Target patient population of the guidelines
The guidelines discuss management of adult pa-
tients (over 18 years of age) of both sexes with symp-
toms suggestive of CDI, with the diagnosis confirmed 
based on current criteria, regardless of the type or sever-
ity of symptoms. In addition, recommendations for man-
aging CDI also include patients with recurrent infection.
1.2.  Development of recommendation 
statements
The clinical practice guidelines are recommendation 
statements aimed at optimising patient care, based on 
the systematic review of evidence as well as evaluation 
of benefits and losses of alternative medical care [1].
Table II. Quality of evidence according to GRADE
Quality of evidence
High One or more high-quality, well-constructed, randomised controlled trials (RCT) have provided consistent results for direct 
implementation in clinical practice. It means that further research is unlikely to affect the expected outcomes
Moderate Supported by RCTs but with significant limitations (i.e. biased assessment of therapeutic outcomes, high patient loss during 
follow-up, no blinding, unexplained heterogeneity), indirect evidence from similar (but not identical) study populations, and 
studies with very few patients or observed events (end-points).
In addition, there is some evidence from well-designed, non-randomised controlled trials, from well-constructed cohort or 
case-control analytical studies, and from many case series with or without an intervention.
It means that further research can probably have an important impact on the expected outcomes and can change them
Low Observational studies, typically of low quality due to a risk of errors. This means that further research will almost certainly 
have a significant impact on the expected outcomes and will most likely change them
Very low The evidence is contradictory, of low quality, or with no results; therefore, the balance of benefits and risks cannot be 
determined.
It means that the expected outcomes are highly uncertain as evidence or are even unavailable or do not allow one to draw 
any conclusions
Table I. Strength of recommendation statement 
according to the GRADE rating system
Strength of recommendation statements
Strong The benefits considerably outweigh the risks and 
losses, or vice versa. Usually, the recommendation 
statement is tagged ‘recommended’
Weak The benefits precisely balance the risks and losses. 
Usually, the recommendation statement is tagged 
‘suggested’
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The practice guidelines were developed by a mul-
tidisciplinary panel of experts in epidemiology, diag-
nosis, infection control, and treatment of adult CDI 
patients. Only original studies (optimally prospective, 
randomised, double-blinded, placebo-controlled studies) 
were incorporated for the development of the guide-
lines. In the absence of such studies, the evidence of 
lower quality was considered, including observational 
and retrospective studies (excluding case series and 
case reports), as well as systematic reviews and me-
ta-analyses. The source data were found in the follow-
ing electronic databases: PubMed, NCBI, Cochrane Li-
brary, Researchgate, and GoogleScholar, as well as in 
the recommendation statements and guidelines pub-
lished on the websites of international scientific soci-
eties. The literature review and analysis were limited to 
articles published in either English or Polish.
The evaluation of the quality of evidence and the 
strength of recommendation statements was support-
ed by the Grading of Recommendations Assessment, 
Development, and Evaluation system (GRADE) (Tables I 
and II). Delphi voting was implemented for the final 
decision making. The acceptance level for each rec-
ommendation statement was assessed by the expert 
panel on a five-point scale (A–E) and determined by 
the agreement level (Table III). Each recommendation 
statement was discussed taking into consideration the 
scientific evidence used for its formulation, covering the 
relationship between the guidelines and the scientific 
data. Based on the acceptance level, the consensus be-
tween experts was considered high when 80% or more 
of voters chose A or B categories. When the results 
were below 80%, the agreement level was deemed low.
1.2.1. Recommendation statement interpretation
The graphic interpretation scheme is shown below. 
Each recommendation statement consists of three parts 
regarding its strength, the quality of evidence, and the 
distribution of the expert votes.
–  The strength of the recommendation statement is 
considered strong or weak according to the GRADE 
rating system.
–  The quality of the evidence is considered high, mod-
erate, low, or very low according to the GRADE rating 
system.
–  The acceptance level by experts (rating scale).
Table III. The agreement level of votes
Category Agreement level
A Fully accepted
B Accepted with some objections
C Accepted with major objections
D Rejected with some objections
E Fully rejected
Categories A and B selected by ≥ 80% experts High level of agreement between experts
Categories A and B selected by < 80% experts Low level of agreement between experts
Example
4.1. Recommendation statement 10
Private rooms and/or dedicated toilets for isolated CDI patients
We recommend isolation for CDI patients, i.e. accommodation in private rooms with a separate toilet pre-
vents infection transmission to other patients. When there are not enough toilets or single rooms, priority 
should be given to patients with stool incontinence, who should be placed in single rooms.
Strength: strong; quality of evidence: moderate.
Voting
A – %; B – %; C – %; D – %; E – % ← percentage of experts in favour of the recommendation statement.
 Agreement level: ← When ≥ 80% chose category A or B, the agreement level was high; otherwise it was low.
RECoMMEnDATIon strength tells the clini-
cians whether they should or can implement 
the recommendation (strong), or if they should 
consider it but not necessarily implement it, i.e. 
they have freedom to choose.
QUAlITy of EVIDEnCE 
tells the clinicians what type 
of research backs up the rec-
ommendation statement.
ToGEThER the recom-
mendation strength and 
the quality of evidence 
are assessed by the ex-
perts (agreement level). 
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average age of 75.0 years. The incidence of HA CDI was 
2.4 cases/10,000 man-days. As for 126/593 (21.2%) 
of the hospital surveillance period, no cases of HA CDI 
were observed. The median in-hospital incidence of HA 
CDI was 2.9 cases per 10,000 man-days. The average 
incidence of CDI was the highest in reference hospi-
tals (5.8 cases/10,000 man-days; 95% CI 3.6–7.8 cas-
es/10,000 man-days). It was also the lowest in com-
munity hospitals (2.8 cases/10,000 man-days; 95% CI: 
2.1–3.5 cases/10,000 man-days; p = 0.001). Estonia, 
Lithuania, and Poland reported the highest incidence 
of HA CDI.
The incidence of CA CDI was 0.8 cases/10,000 man-
days, with the highest rates being reported by Estonia, 
France, and Poland [3].
Clostridium difficile is a Gram-positive, obligate 
anaerobe and a spore-forming bacterium, which was 
first identified in 1935 [4]. The most common route of 
transmission is faecal-oral. At the beginning of the 21st 
century, an increase in CDI incidence was observed due 
to the rapidly spreading NAP1 strain (North American 
Pulse Field Type 1) otherwise known as ribotype 027 
or B1/NAP1/027. This strain caused both an increased 
risk of developing hospital-based endemic foci and a re-
gional increase in CDI incidence. The endemic strain 
B1/NAP1/027 is hypervirulent, characterised by an in-
creased ability to form spores, high resistance to fluo-
roquinolones, and it more often causes infections with 
severe clinical course [5, 6].
Over the last decade, one of the most serious ep-
idemiological problems was the increase in C. difficile 
infection rate in hospitals. Based on Kronika Epidemio-
logiczna (pol. the epidemiological chronicle), in 2016 
C. difficile infections accounted for 28.3% of all regis-
tered outbreaks of hospital-acquired infections. There 
were 8716 cases reported, of which 540 were fatal [7].
According to the data from the National Institute 
of Public Health – National Institute of Hygiene in Po-
land, in 2017 the incidence of CDI was 30.2 per 100,000 
inhabitants. There were 11,667 reported cases. Hospi-
tal stay was required in 88.1% of patients [8]. In the 
years 2011 to 2013, clinical studies were conducted in 
13 hospitals in Poland, proving that PCR ribotype 027 
CDIs predominate (62%). The second most common 
aetiological factor is ribotype 176, responsible for 14% 
of CDIs [6].
Risk factors of CDI
CDI infections are significantly more common in pa-
tients with risk factors, including: antibiotic therapy, age 
over 65 years, hospitalisation for more than 4 weeks or 
stay in a long-term medical care facility, comorbidities, 
diseases associated with immunosuppression or che-
2. Epidemiology
2.1. Recommendation 1
Recommended definition of CDI
To monitor infection sites and to increase compara-
bility between analyses, the widely available stan-
dard definitions of primary infection should be used, 
including: (1) healthcare-onset (HO) CDI – the site of 
primary infection is in a healthcare facility, e.g. hospi-
tal; (2) community-onset, healthcare facility-associat-
ed (CO-HCFA) CDI – infection occurring in a non-hos-
pital environment following contact with healthcare 
facilities; and (3) community-associated (CA) CDI – 
infection with no relation to a hospital stay.
(Good practice recommendation)
Voting:
A – 83.3%; B – 16.7%; C – 0%; D – 0%; E – 0%.
Agreement level: hIGh.
2.2. Recommendation 2
Recommendation on minimal supervision for insti-
tutions with limited resources
Implement HO-CDI surveillance in all hospitals to 
identify increased risk or outbreaks of CDI in the 
healthcare facility.
(Recommendation: weak; quality of evidence: low)
Voting:
A – 50%; B – 33.3%; C – 16.7%; D – 0%; E – 0%.
Agreement level: hIGh.
2.3. Recommendation 3
Recommendation on the best way to express CDI 
incidence and prevalence
Express HO-CDI prevalence as the number of cases 
per 10,000 man-days of treatment. Express CO-HCFA 
prevalence as the number of cases per 1000 patient 
admissions.
(Good practice recommendation)
Voting:
A – 83.3%; B – 16.7%; C – 0%; D – 0%; E – 0%.
Agreement level: hIGh.
2.1.1./2.2.1./2.3.1. Discussion
Clostridium difficile infection is a major cause of 
antibiotic-associated diarrhoea. It is responsible for 
15–25% of all cases, with a considerable increase in 
the number of CDI cases in the 21st century [2]. In 2016 
a report was issued evaluating 7711 CDI cases from 
20 countries. The number of healthcare-associated (HA) 
CDI cases was 5756 (74.6%), and the number of com-
munity-associated (CA) CDI cases was 1955 (25.4%). In 
the hospital, from which the analysed data were ob-
tained, men constituted 44.9% of patients, with the 
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motherapy, and use of proton pump inhibitors. Chronic 
diseases that promote CDI infection include: chronic 
kidney disease, dialysis, cystic fibrosis, diabetes, stroke, 
malnutrition, alcoholism, chronic heart disease, chronic 
lung disease, primary and secondary immunity disor-
ders – including HIV, cancer, and non-specific inflam-
matory bowel diseases [4]. Almost every antibiotic used 
can be a risk factor for the development of CDI; even 
the drugs used to treat CDI – vancomycin and metro-
nidazole – are a risk factor for the disease. Antibiotics 
were divided into three groups, depending on the de-
gree of risk of CDI induction (Table IV) [5].
Clostridium difficile colonisation  
and infection
Clostridium difficile transmission in a healthcare 
facility is most likely the result of faecal-oral spread 
or direct contact with a contaminated environment. 
The asymptomatic colonisation rate with C. difficile is 
3–26% among adult in-patients. The rate of asymp-
tomatic C. difficile presence in stool in adults is < 2%. 
Research suggests that individuals with asymptomatic 
colonisation for a prolonged time have a reduced risk of 
developing CDI. Long-term colonisation may be depen-
dent on the increase of anti-A and anti-B toxin serum 
antibodies [9].
The main routes of C. difficile transmission include: 
hands of the medical staff and a polluted environment, 
an inadequately cleaned room previously occupied by 
a CDI patient, and contaminated thermometers and 
other medical equipment.
Different forms of CDI are summarised in Table V 
[10–12].
2.4. Recommendation 4
Recommendation on CDI surveillance in the face  
of high endemic or epidemic rates
Classify data based on patient location in order for 
appropriate control measures when CDI incidence ex-
ceeds average rates and/or it is impossible to limit 
the disease spread, or an outbreak occurs.
(Recommendation: weak; quality of evidence: low)
Voting:
A – 83.3%; B – 16.7%; C – 0%; D – 0%; E – 0%.
Acceptance level: hIGh.
Table IV. Antibiotics and the risk of CDI
high risk Moderate risk low risk
Fluoroquinolones
2nd and 3rd generation cephalosporins
Clindamycin
Ampicillin
Broad-spectrum penicillins with inhibitors 
(except for ticarcillin with clavulanate and 
piperacillin with tazobactam)
Macrolides
Trimethoprim/sulfamethoxazole
Other penicillins
Sulphonamides
Aminoglycosides
Bacitracin
Metronidazole
Teicoplanin
Vancomycin
Rifampicin
Chloramphenicol
Tetracycline
Carbapenems
Daptomycin
Tigecycline
Table V. Severity of CDI
Severity ShEA and IDSA criteria [10] Criteria by  
Zar et al. [11]
Criteria accepted by the national 
Program for Antibiotic Protection 
according to McDonald et al. [12]
Severe Leukocytosis
≥ 15,000/mm3 
and/or
creatinine ≥ 1.5 × greater than before 
the infection onset
At least 2 of the following:
– age ≥ 60
– temperature ≥ 38.3°C
– albumin ≤ 2.5 g%
– leukocytosis ≥ 15 000/mm3
 
and/or
–  pseudomembranes on endoscopy 
and/or
– treatment in ICU
Within 30 days since CDI diagnosis:
–  treatment in ICU due to 
complications (e.g. shock, 
catecholamine infusion) or
–  surgery due to complications (toxic 
megacolon, perforation, ineffective 
medical treatment) 
Fulminant Leukocytosis > 50,000/mm3
 
– – 
Severe 
complicated
Ileus, perforation, or shock – Toxic megacolon, perforation, 
ineffective medical treatment, or death
SHEA – Society for Healthcare Epidemiology of America, IDSA – Infectious Diseases Society of America.
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2.4.1. Discussion
Special supervision is required in patients with di-
arrhoea, toxic megacolon, or severe ileus [13], as well 
as in those testing positive or with pseudomembranes 
on endoscopy or microscopy. The occasional infection 
is a new first episode of symptoms, i.e. no symptoms 
were present within the preceding 8 weeks; positive 
test result – enzyme-linked immunosorbent assay (EIA) 
or nucleic acid amplification assay (NAAT). The current 
infection is the onset of symptoms and a positive stool 
test following an episode, with a positive test result 
within the previous 2 to 8 weeks [14].
Surveillance of specific communities in the event 
of an outbreak in non-hospitalised individuals should 
be considered to determine the incidence trends in the 
given population. Adequate classification of patients by 
place of residence can improve infection control.
3.  Symptoms, differential diagnosis, 
and diagnostic criteria
3.1. Recommendation 5
Preferred patient population for testing, most sus-
pected of CDI
Patients with new, unexplained diarrhoea with ≥ 3 
loose stools within 24 h are the preferred target pop-
ulation for CDI testing.
(Recommendation: weak; quality of evidence: very 
low)
Voting:
A – 50%; B – 50%; C – 0%; D – 0%; E – 0%.
Acceptance level: hIGh.
3.1.1. Discussion
Testing for C. difficile infection should include indi-
viduals with an unexplained new episode of three or 
more loose stools within 24 h. The optimal number of 
loose stools required for CDI testing depends on the 
likelihood of infection (high vs. low) and potential con-
founding factors such as an underlying disease and sur-
gical interventions. Potential confounding factors may 
contribute to an increased risk of antibiotic-associated 
diarrhoea. When a patient presents with diarrhoea that 
cannot be attributed to any disorder, testing for C. dif-
ficile infection is recommended. Testing should also be 
conducted when diarrhoea persists despite discontinu-
ation of treatment, e.g. with laxatives.
Some conditions and medical interventions relat-
ing to the diarrhoea itself, such as irritable bowel syn-
drome (IBS) or enteral feeding, are associated with an 
increased risk of CDI. In clinical practice, it is difficult 
to exclude CDI in patients with new-onset or severe 
diarrhoea. The clinical criteria for the diagnosis of CDI 
have changed along with increasing awareness of C. dif-
ficile infection. It is worth mentioning that the num-
ber and frequency of loose stools justifying CDI testing 
have decreased over the last 40 years. In 1974, Tedesco 
et al. defined diarrhoea as > 5 stools a day [15]. In 2013, 
Johnson et al. defined diarrhoea as > 3 loose stools or 
watery bowel movements within 24 h [16]. Clinicians 
can improve the test accuracy only by examining pa-
tients suspected of C. difficile infection.
3.2. Recommendation 6
The most effective methods (in terms of positive 
and negative predictive values) to identify patients 
at risk of a clinically significant C. difficile infection 
based on stool testing
Use a stool toxin test as part of a multi-step algo-
rithm, i.e. 1. glutamate dehydrogenase (GDH) and 
toxin; 2. GDH plus toxin, confirmed by nucleic acid 
amplification test (NAAT); or 3. NAAT plus toxin. This 
algorithm is recommended rather than NAAT alone 
for all samples sent to the laboratory when there are 
no local guidelines for stool sampling.
(Recommendation: weak; quality of evidence: low)
Voting:
A – 66.6%; B – 16.7%; C – 16.7%; D – 0%; E – 0%.
Acceptance level: hIGh.
3.2.1. Discussion
Clostridium difficile infection should be suspect-
ed in patients with diarrhoea (≥ 3 loose stools within 
24 h) of unexplained origin. Many laboratory studies 
can be implemented in CDI diagnosis. Those methods 
are based on direct detection of bacteria as well as 
one or both major toxins (A and B) in stool. Table I lists 
those methods in order of decreasing analytical sensi-
tivity. Toxicological cultures include selective medium 
or its variant and anaerobic incubation for several days. 
Later the organism is identified using several methods 
such as laser desorption, matrix-assisted ionisation 
mass spectrometry. The characteristic ‘horse barn’ smell 
often heralds the presence of C. difficile. After pathogen 
identification, testing for toxins should be performed to 
confirm infection with the toxin-producing strain. Tox-
icological culture is one of the gold standard methods, 
to which other studies are compared.
Another reference method is a cell culture cytotoxic-
ity neutralisation assay (CCNA) [17]. It allows for direct 
detection of toxins in stool. First, stool filtrate is pre-
pared and administered to an appropriate monolayer 
cell line such as Vero cells or human fibroblasts. After 
incubation, the cells are observed for cytopathic effect 
(CPE). The control study is carried out simultaneously 
using neutralising antibodies to Clostridium sordellii or 
C. difficile to confirm that CPE is caused by the toxins 
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produced by C. difficile and not by other substances in 
the stool. Incubation is continued for a maximum of 
48 h, but positive results can often be obtained after 
overnight incubation. This method is time-consuming 
and lacks standardisation; however, it is characterised 
by high sensitivity and specificity. CCNA has been sup-
planted by faster antigen and molecular testing meth-
ods. Enzyme immunoassays (EIAs) detect proteins in 
the tested material using monoclonal or polyclonal 
antibodies linked to an enzyme. At first, the tests only 
detected toxin A; however, with time both toxins A and 
B started to be detected. Toxins A and B and hydrolytic 
enzymes including hyaluronidase, chondroitin sulfa-
tase, gelatinase, and collagenase are virulence factors 
of C. difficile. Toxin A is an enterotoxin stimulating pro-
duction of cytokines, chemokines, and substance P. In 
addition, toxin A stimulates neutrophil dipeptidase pro-
duction in the intestinal lumen, leading to disruption of 
connections between enterocytes and their apoptosis. 
Toxin B is a cytotoxin causing apoptosis of enterocytes 
damaged by toxin A. Both toxin A and toxin B inactivate 
Rho GTPase (guanosine triphosphate hydrolase) leading 
to depolymerisation of actin fibres and damage to the 
skeleton of the colon epithelial cells, resulting in pseu-
domembrane formation. They consist of neutrophils, 
fibrin, mucus, and enterocyte residues. Microscopically, 
pseudo-membranes form of yellowish-white deposits 
on the inflamed colonic mucosa.
The most frequently used method in CDI diagnosis 
is based on direct detection of C. difficile toxin in a stool 
sample. In selected patients, e.g. with inflammatory bowel 
disease, it is recommended that CDI be tested for at every 
disease exacerbation. The most commonly used method 
is the enzyme immunoassay (EIA) [17, 18], which gives 
quick results, i.e. after 1–2 h. The sensitivity is 75–85% 
and specificity 95–100%. EIAs use monoclonal or poly-
clonal antibodies to detect C. difficile toxins, and many 
commercial tests are available. Due to poor performance 
of EIA tests, GDH (glutathione dehydrogenase) immuno-
assays and molecular tests for detecting toxin genes have 
been developed [19, 20]. Glutamate dehydrogenase im-
munoassays detect the metabolic enzymes present in all 
C. difficile isolates. The antigen detected by the GDH test 
is not specific only to C. difficile toxin-producing strains, it 
is also present in non-toxin-producing C. difficile bacteria. 
The combination of two tests allows for a faster result and 
better sensitivity compared to the EIA tests alone [20]. In 
2009, the nucleic acid amplification test (NAAT) was used 
to detect CDI. The test is based on the PCR (polymerase 
chain reaction) method and has a higher sensitivity (80–
100%) and specificity (87–99%) compared to the EIA test. 
The NAAT test has limitations in the form of high costs of 
implementation and difficulties in interpretation.
Table VI shows the available tests for CDI detection 
in order of decreasing sensitivity.
The optimal diagnostic method for CDI is hard to 
achieve.
Patients may also be carriers of toxin-producing 
strains without clinically apparent disease. Diarrhoea 
in hospitalised patients is common, and C. difficile is 
responsible for less than 30% of cases. Based on current 
understanding, it is difficult to indicate which method 
is the most useful in CDI detection. Tables VII and VIII 
compare the available diagnostic tests for CDI [21–27].
Table VI. Available tests for CDI detection in order of decreasing sensitivity [1]
Test Sensitivity Specificity Detected substance
Bacterial cultures High Low* C. difficile vegetative forms or spores
Nucleic acid amplification test High Low/moderate C. difficile nucleic acid (toxin genes)
Glutamate dehydrogenase High Low* C. difficile common antigen
Cytotoxicity neutralisation test 
on a cell culture
High High Free toxins
Immunological tests detecting 
toxins A and B
Low Moderate Free toxins
*The test should be accompanied by toxin detection methods.
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Table VII. Evidence for the recommended diagnostic tools for C. difficile infection diagnosis
Evidence for diagnostic tools Design number of 
participants
limitations Quality of evidence 
(GRADE)
References,  
first author
GDH and NAATs have the 
highest sensitivity, but low PPV 
in asymptomatic patients; all 
tests had high NPV regardless of 
symptoms
Observational study, 
patient interview 
and clinical 
assessment
150 Low number of 
participants; only 
basic lab tests were 
assessed in real time
Dubberke [21]
Toxins – negative, NAAT – positive, 
untreated patients showed no side 
effects. The CDI relapse was more 
common when both NAAT and 
toxins were positive rather than 
when only NAAT was positive (31% 
vs. 14%; p = 0.03)
Retrospective 
observational study
128 Low number of 
participants
Kaltsas [22]
No difference in positive 
evaluation for EIA toxicity between 
patients with mild and severe 
disease (49% vs. 58%; p = 0.31)
Observational 
study, prospective 
study, retrospective 
assessment of 
patient data
299 Single-centre study Humphries [23]
Complications were more common 
with positive NAAT and GDH/EIA/
CCNA compared to isolated positive 
NAAT (39% vs. 3%; p < 0.001)
Prospective cohort 
study; observational
1321 Only some samples 
were tested using 
the gold standard
Longtin [24]
Patients with positive CCNA or 
GDH/EIA showed higher all-cause 
mortality compared to patients 
with positive NAAT or TC (p = 0.001) 
Multi-centred 
observational study
12420 Limited clinical data Planche [25]
Patients testing positive for toxins 
with EIA showed longer duration 
of diarrhoea, more CDI-related 
complications, greater CDI-related 
mortality compared to patients 
testing negative for toxins but 
with positive PCR test result  
(8.4% vs. 0.6%, p = 0.001)
Prospective 
single-centre trial, 
observational, 
cohort
1416 Single-centre study Polage [26]
Table VIII. Evidence for recommended diagnostic tests for CDI. It is preferred to use NAAT alone or as a part of 
a multi-step algorithm (i.e. GDH plus toxin supported by NAAT or NAAT plus toxin) rather than testing for toxins 
when there are established institutional procedures for stool sampling
Evidence for diagnostic 
tests
Study number of 
participants
limitations Quality of 
evidence (GRADE)
References,  
first author
PCR was more sensitive 
(93.3%) than EIA (73.3%) 
for toxin detection and 
direct cytotoxicity test 
(76.7%), when used in 
patients meeting clinical 
criteria for CDI
Observational; 
patient interviews
350 Peterson [27]
Using clinical diagnosis 
as reference, PCR was 
more sensitive than CCNA 
and GDH (99.1% vs. 51% 
83.8%). Clinically confirmed 
in 91.5% of cases
Prospective double-
centre study
1051 Various order 
of tests; limited 
statistical analysis; 
limited patient 
observation
Berry N, Sewell B, Jafri S,  
et al. Real-time polymerase 
chain reaction correlates 
well with clinical diagnosis of 
Clostridium difficile infection. 
J Hosp Infect 2014; 87: 109-14
CCNA – cell cytotoxicity neutralisation assay, CDI – Clostridium difficile infection, EIA – enzyme immunoassay, GDH – glutamate dehydrogenase, NAAT – nucleic 
acid amplification test, NPV – negative predictive value, PCR – polymerase chain reaction, PPV – positive predictive value, TC – toxin-producing strain culture.
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3.3. Recommendation 7
The most sensitive method of CDI diagnosis in 
stool in patients at risk of CDI based on clinical 
presentation
If stool samples were obtained from patients who 
were at risk of CDI based on clinical presentation, 
use NAAT or a multi-step algorithm to test: 1. GDH 
plus toxin; 2. GDH plus toxin and NAAT; and 3. NAAT 
plus toxin. Those methods are preferred over toxin 
detection itself, when there are established institu-
tional criteria for stool sampling.
(Recommendation: weak; quality of evidence: low)
Voting:
A – 0%; B – 100%; C – 0%; D – 0%; E – 0%.
Acceptance level: hIGh.
3.3.1. Discussion
If patients are carefully examined for clinical symp-
toms of CDI (at least three loose stools within 24 h, with 
a history of exposure to antibiotics), then the best way 
of further evaluation is a multi-step clinical algorithm. 
GDH plus toxin or GDH plus toxin/NAAT or NAAT plus 
toxin. A two- or three-step algorithm has greater diag-
nostic accuracy compared to single-step testing. Recom-
mended diagnostic algorithms are shown on Figure 1. 
Patient with CDI symptoms Patient without CDI symptoms
GDH testing Do not run any tests
Toxin A/B or cytotoxicity 
neutralisation
Positive Negative – CDI excluded
Positive – presence of toxin-
producing C. difficile –  
CDI confirmed
Negative – Absence of toxin-
producing C. difficile –  
CDI excluded
Positive – CDI confirmed Negative NAAT or cultures of toxin-producing C. difficile
Patients with CDI symptoms
GDH testing + Toxin A/B
Test (–) and Toxin (–) = lack of toxin-
producing C. difficile
Test (+) and Toxin (+) = confirmed CDI Test (+) and Toxin (–)
Positive = presence of toxin-producing 
strain
Negative = absence of toxin-producing 
strain
 NAAT or cultures of toxin-producing strain
figure 1. Recommended diagnostic algorithms for C. difficile infection
GDH – glutamate dehydrogenase, NAAT – nucleic acid amplification test, CDI – C. difficile infection.
A
B
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3.4. Recommendation 8
The role of repeated testing. Should repeated test-
ing be considered in asymptomatic patients, includ-
ing post-treatment control test?
During the same episode of diarrhoea, stool tests 
should not be repeated for 7 days. Stool testing 
should be avoided in asymptomatic patients. Stool 
testing can be performed for epidemiological studies 
in asymptomatic patients.
(Recommendation: strong; quality of evidence: 
moderate)
Voting:
A – 83.3%; B – 16.7%; C – 0%; D – 0%; E – 0%.
Acceptance level: hIGh.
3.4.1. Discussion
The issue of retesting for CDI is strictly linked to the 
accuracy of the testing method. The use of suboptimal 
specificity tests means that multiple repetitions are as-
sociated with a high risk of false positives. In the ab-
sence of CDI suspicion, do not re-test. The use of highly 
sensitive testing strategies (two-stage or three-stage al-
gorithms) means that individual tests have a very high 
negative predictive value (usually > 99%).
3.5. Recommendation 9
The use of lactoferrin or other biological mark-
ers in stool to increase efficacy of CDI diagnosis 
compared to detecting toxin-producing C-difficile 
strains
There is insufficient evidence to recommend using 
biological markers to enhance diagnosis.
(no recommendation)
Voting:
A – 100%; B – 0%; C – 0%; D – 0%; E – 0%.
Acceptance level: hIGh.
3.5.1. Discussion
In the recent years, there has been an increase in 
the number of biomarkers detected in stool used to 
differentiate inflammatory and non-inflammatory diar-
rhoea. Those include lactoferrin, calprotectin, as well as 
IL-8 and IL-1b [28].
Lactoferrin is an iron-binding glycoprotein found in 
neutrophils, and its concentration in the stool is propor-
tional to the neutrophil count in stool [29]. Calprotectin 
is a calcium-binding protein found in the neutrophil cy-
tosol [30, 31]. Secretion of intestinal cytokines such as 
IL-8 and IL-1b was also evaluated. Although the markers 
are used in the diagnosis of irritable bowel syndrome, 
their usefulness in the diagnosis of CDI has not been 
established [32].
4. Infection control and prevention
4.1. Recommendation 10
Isolation of CDI patients
Should separate rooms and toilets be used for iso-
lated CDI patients?
Isolation recommendations for patients with CDI – 
placing patients in separate rooms with separate toi-
lets protects against disease transmission to other 
patients. When there are not enough toilets and sin-
gle rooms, priority should be given to patients with 
stool incontinence, who should be placed in separate 
rooms.
(Recommendation: strong; quality of evidence: 
moderate)
Voting:
A – 100%; B – 0%; C – 0%; D – 0%; E – 0%.
Acceptance level: hIGh.
4.1.1. Discussion
Patients with confirmed or suspected CDI should be 
isolated. This is a preventive measure against infection 
spread in the ward. Additional precautions are often 
implemented, especially when CDI rates are high. The 
‘control packet’ strategy for infection control is used to 
effectively control major CDI foci. It includes hand wash-
ing, isolation, environmental decontamination, and anti-
biotics [33–35]. The basis for CDI prevention and control 
are properly designed hospital rooms and hand washing 
products. Single rooms with private toilets are preferred. 
The effect of single rooms on CDI and other bacterial 
transmission rates was investigated when the ICU of one 
of the hospitals was closed for renovation [36]. It was es-
tablished that the CDI rate decreased by 43%. When pa-
tient grouping is necessary due to a lack of single rooms, 
the patients should be given individual lockers for storing 
private items, which reduces transmission.
4.2. Recommendation 11
Recommendations for cohorting infected or colo-
nised patients with the same pathogen
If cohorting is necessary, it is recommended to group 
patients colonised or infected with the same patho-
gen. CDI patients should not be grouped if there is 
discordance with respect to other drug-resistant 
pathogens such as MRSA – methicillin-resistant 
Staphylococcus aureus or vancomycin-resistant En-
terococcus.
(Recommendation: strong; quality of evidence: 
moderate)
Voting:
A – 83.3%; B – 16.7%; C – 0%; D – 0%; E – 0%.
Acceptance level: hIGh.
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4.2.1. Discussion 
If patient cohorting is necessary, patients infected or 
colonised with the same pathogen should be grouped 
together. Patients with other drug-resistant pathogens 
such as MRSA or vancomycin-resistant Enterococci 
(VRE) should not be grouped together.
4.3. Recommendation 12
Should hospital staff wear gloves and gowns when 
caring for CDI patients?
Hospital staff should wear gloves (recommendation: 
strong; evidence quality: high) and gowns (recom-
mendation: strong; evidence quality: moderate) 
when entering rooms with CDI patients and when 
caring for them.
Voting:
A – 100%; B – 0%; C – 0%; D – 0%; E – 0%
Acceptance level: hIGh.
Voting:
A – 83.3%; B – 16.7%; C – 0%; D – 0%; E – 0%.
Acceptance level: hIGh.
4.3.1. Discussion
Preventive measures include gowns and gloves 
when caring for CDI patients. The hands of the hospital 
staff may be contaminated with C. difficile spores, es-
pecially when they do not wear gloves and are exposed 
to faeces [37]. In addition, when using gloves, remove 
them carefully so as not to contaminate your hands 
and forearms. It is recommended that protective gowns 
be worn due to the risk of contamination of uniforms. 
Contaminated uniforms can be a source of C. difficile 
transmission.
4.4. Recommendation 13
When should isolation be established?
Safety precautions should be established for pa-
tients suspected of CDI while waiting for the results 
of C. difficile testing, when the results cannot be ob-
tained on the same day.
(Recommendation: strong; quality of evidence: 
moderate)
Voting:
A – 83.3%; B – 16.3%; C – 0%; D – 0%; E – 0%.
Agreement level: hIGh.
4.4.1. Discussion
If there is a delay in test results, safety measures 
should be introduced similar to those for confirmed 
CDI. Patients with suspected CDI should be subjected 
to preventive safety measures while waiting for CDI 
confirmation [38]. 
4.5. Recommendation 14
how long should the isolation last?
Safety measures restricting contact with the patient 
should be continued up to at least 48 h after resolu-
tion of diarrhoea. 
(Recommendation: weak; quality of evidence: low)
Voting:
A – 50%; B – 33.3%; C – 16.7%; D – 0%; E – 0%.
Agreement level: hIGh.
It is appropriate to extend safety measures and re-
strict the contact with the patient until discharge if 
the CDI incidence rate is high despite introduction of 
standard infection control measures.
(Recommendation: weak; quality of evidence: low)
Voting:
A – 33.3%; B – 50%; C – 16.7%; D – 0%; E – 0%.
Agreement level: hIGh.
4.5.1. Discussion
According to British recommendations, safety mea-
sures should be continued up to 48 h after resolution of 
diarrhoea [39]. The average time to diarrhoea resolution 
is 4.2 days. There is no evidence for reduced CDI rate in 
response to prolongation of safety measures.
4.6. Recommendation 15
Which hand washing method is recommended 
(assuming glove use) during care for isolated CDI 
patients?
In the case of high CDI rates or an outbreak, routine 
hand washing with soap and water is the preferred 
method instead of alcohol-based products. Hand 
washing with soap and water before and after con-
tact with CDI patients shows superior efficacy in re-
moving C. difficile spores.
(Recommendations: strong; quality of evidence: 
moderate)
Voting:
A – 66.6%; B – 16.7%; C – 16.7%; D – 0%; E – 0%.
Agreement level: hIGh.
Hand washing using water and soap is preferred 
when there is direct contact with faeces or probably 
contaminated skin region, e.g. perineal area. 
(Good practice recommendation)
Voting:
A – 83.3%; B – 16.7%; C – 0%; D – 0%; E – 0%.
Agreement level: hIGh.
4.6.1. Discussion
The hands of the medical staff are often the source 
of C. difficile infection. A prospective study on 27 CDI 
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patients showed that C. difficile can often contaminate 
various body regions including the groin, chest, abdo-
men, forearms, and hands. Contamination of chest or 
abdominal skin persisted after resolution of diarrhoea 
[40]. Patients with CDI symptoms are the main source 
of disease transmission. Their faeces contain a large 
number of spores, which are transferred/excreted to the 
environment. Contamination of skin, clothes, bedsheets, 
and surroundings have been appropriately called faecal 
veneer [40, 41]. The hands of the medical personnel are 
an important vector of spore transmission onto vulnera-
ble patients [41]. Patients may also become contaminat-
ed with spores due to direct contact with contaminated 
surfaces or appliances. If patient isolation in a single 
room with a separate bathroom is impossible, then hand 
washing is of upmost importance to prevent the disease 
transmission between patients, medical staff, and visi-
tors [42]. It was proven that C. difficile can be isolated 
from hands and faeces of asymptomatic medical staff. 
Moreover, spores were also found in sewage, soil, and 
patients’ houses. It is epidemiologically significant that 
C. difficile can survive for up to 5 months on the floor.
4.7. Recommendation 16
The role of the patient’s bath in CDI prevention
Patients should be encouraged to wash their hands 
and take a shower in order to decrease the amount 
of C. difficile spores on the skin.
(Good practice recommendation)
Voting:
A – 100%; B – 0%; C – 0%; D – 0%; E – 0%.
Agreement level: hIGh.
4.7.1. Discussion
The patient can transport C. difficile spores on his or 
her contaminated hands. Hand washing and disinfec-
tion are important to prevent CDI recurrence. Patients 
should take a bath or shower regularly to decrease the 
number of spores on their skin [43]. 
4.8. Recommendation 17
Recommendations for cleaning non-critical equip-
ment and accessories after their use by CDI patients
Use disposable equipment if possible. Ensure that 
reusable equipment is thoroughly cleaned and disin-
fected, especially with use of sporicidal disinfectants 
compatible with the equipment. 
(Recommendation: strong; quality of evidence: 
moderate)
Voting:
A – 83.3%; B – 16.7%; C – 0%; D – 0%; E – 0%.
Agreement level: hIGh.
4.9. Recommendation 18
The role of manual final disinfection using sporicid-
al disinfectants active against C. difficile in isolated 
CDI patients
Cleaning the rooms using sporicidal disinfectants 
should be considered in combination with other 
measures preventing CDI endemic infections in the 
case of an epidemic or if there is evidence of recur-
ring CDI in the same room. 
(Recommendation: weak; quality of evidence: low)
Voting:
A – 33.3%; B – 66.7%; C – 0%; D – 0%; E – 0%.
Agreement level: hIGh.
4.10. Recommendation 19
Assessment of cleaning effectiveness 
The goal of the quality of cleaning assurance is to 
define the rules of the cleaning effectiveness assess-
ment.
Voting:
A – 100%; B – 0%; C – 0%; D – 0%; E – 0%.
Agreement level: hIGh.
4.11. Recommendation 20
The role of automatic terminal sporicidal disinfec-
tion against C. difficile in isolated CDI
Until now there have only been a few studies recom-
mending the use of automatic terminal disinfection 
in CDI prevention.
(non-recommended)
Voting:
A – 16.7%; B – 66.6%; C – 0%; D – 0%; E – 16.7%.
Agreement level: hIGh.
4.11.1. Discussion
There are technologies of contactless disinfection, 
for example ultraviolet light systems (UVL) or hydrogen 
peroxide vapours (HPV). Technology of contactless dis-
infection using ultraviolet light might be successful in 
the prevention of CDI infections.
4.12. Recommendation 21
The role of everyday sporicidal disinfection
For CDI prevention, everyday cleaning using dedi-
cated sporicidal disinfectants should be considered, 
especially in the case of an epidemic, pandemic, or 
recurrent cases of CDI.
(Recommendation: weak; quality of evidence: low)
Voting:
A – 16.7; B – 66.6%; C – 16.7%; D – 0%; E – 0%.
Agreement level: hIGh.
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4.12.1. Discussion
Everyday cleaning using sporicidals decreases 
contamination with C. difficile. Available disinfectants 
include the following: hypochlorite-based solution 
(500 ppm of chlorine), quaternary ammonium com-
pounds, whitening tissues with 0.55% active chlorine, 
and peracetic acid-based products [1, 44].
4.13. Recommendation 22
The necessity and usefulness of identification of 
asymptomatic carriers of C. difficile with further 
isolation of C. difficile carriers
There is a lack of evidence for compulsory screening 
of asymptomatic carriers for their isolation or imple-
mentation of safety measures.
(not recommended)
Voting:
A – 50%; B – 16.7%; C – 0%; D – 33.3%; E – 0%.
Agreement level: loW.
4.14. Recommendation 23
The role of proper antibiotic therapy in control of 
CDI rate
In order to minimise the risk of CDI development, 
the frequency and duration of high-risk antibiotic 
therapy should be limited. Moreover, the number of 
prescribed antibiotics should be limited as well.
(Recommendation: strong; quality of evidence: 
moderate)
Voting:
A – 100%; B – 0%; C – 0%; D – 0%; E – 0%.
Agreement level: hIGh.
The national program of rational antibiotic use 
should be implemented.
(Good practice recommendation)
Voting:
A – 100%; B – 0%; C – 0%; D – 0%; E – 0%.
Agreement level: hIGh.
4.14.1. Discussion
In the case of a CDI epidemic it is important to im-
plement supervision of the used antibiotics. The pro-
gram of antibiotic rational use should be implemented. 
The frequency and duration of antibiotic therapy may 
have an impact on CDI development. The use of a con-
siderable number of antibiotics (about four) is a signif-
icant risk factor of CDI progression, while the number 
of C. difficile infections increases with the number of 
prescribed antibiotics [1]. CDI risk is associated with 
increased dosage, the number of antibiotics, and the 
duration of therapy. Adjusted hazard ratio (HR) of pa-
tients receiving two, three, four, or five antibiotics was, 
respectively, 2.5 (95% CI: 1.6–4.0), 3.3 (95% CI: 2.2–5.2), 
and 9.6 (95% CI: 6.1–15.1) times higher compared to 
patients with one drug. It is important to minimise the 
duration of drug administration and verify the validity 
of antibiotic therapy. Hospitals should implement anti-
biotic management programs. Benefits from these pro-
grams are as follows: improvement of the treatment 
results, decrease of adverse events such as CDI, and 
improvement of sensitivity to antibiotics [45, 46].
4.15. Recommendation 24
Decrease the frequency and duration of antibiotic 
therapy
In order to decrease the risk of CDI, the frequency and 
duration of high-risk antibiotic therapy and the num-
ber of prescribed antibiotics should be minimised.
(Recommendation: strong; quality of evidence: 
moderate)
Voting:
A – 100%; B – 0%; C – 0%; D – 0%; E – 0%.
Agreement level: hIGh.
4.15.1. Discussion
Decrease of antibiotic use may be the best measure 
to limit the CDI infection rate in the case of an epidem-
ic. Unnecessary antibiotic use should be avoided, and 
the duration of antibiotic therapy should be shortened. 
4.16. Recommendation 25
Targeted antibiotic therapy for CDI control
The type of antibiotics used should reflect the lo-
cal epidemiological situation and C. difficile strains. 
Reduced used of fluoroquinolones, clindamycin, and 
cephalosporins (except for surgical antibiotic preven-
tion) should be taken into consideration. 
(Recommendation: strong; quality of evidence: 
moderate)
Voting:
A – 100%; B – 0%; C – 0%; D – 0%; E – 0%.
Agreement level: hIGh.
4.17. Recommendation 26
The role of proton-pump inhibitors (PPI) use reduc-
tion in CDI prevention
There is an epidemiological association between PPI 
and CDI. If there are no definite indications for PPI 
therapy, it should be discontinued. There are insuf-
ficient data to indicate cessation of PPI therapy as 
a CDI prevention measure.
(non-recommended)
Voting:
A – 83.3%; B – 16.7%; C – 0%; D – 0%; E – 0%.
Agreement level: hIGh.
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4.17.1. Discussion
Many studies reported the associations between PPI 
and CDI [47, 48]. Despite clinical data indicating a con-
stantly increased risk of CDI in patients receiving PPI 
therapy, the impact of PPI on CDI incidence is still not 
clearly established. Many clinical trials were character-
ised by data heterogeneity, the influence of unidentified 
confounding factors, or lack of dose-dependent effect. 
Because of an unclear association between PPI therapy 
and CPI development, PPI therapy with no clear indica-
tions should be discontinued.  
4.18. Recommendation 27
Usefulness of probiotics in primary CDI prevention
At the moment there are insufficient data about the 
role of probiotics in primary CDI prevention, and thus 
no clear recommendation can be given.
(not recommended)
Voting:
A – 50%; B – 16.7%; C – 16.7%; D – 16.7%; E – 0%.
Agreement level: loW.
4.18.1. Discussion
The literature gives contradictory information about 
the influence of probiotics in C. difficile prevention. 
Lactobacillus plantarum 299 v (Lp299v) colonises 
healthy individuals’ digestive tract mucosa following 
oral administration. Its excellent adhering properties 
are a result of binding to mannose of the mucosal cells. 
This strain, due to its adherence, colonises rectal mu-
cosa and is able to survive for up to 11 days after the 
supplementation is stopped, which prevents adherence 
of other pathogenic bacteria. Moreover, studies showed 
that Lp299v stimulates production of mucin by intesti-
nal cells [49]. Lp299 is vulnerable to antibiotics such 
as ampicillin, erythromycin, and trimethoprim/sulfame-
thoxazole [50, 51]. Studies including patients receiving 
antibiotic therapy supplemented by either Lp299v or 
genomically similar L. plantarum 299 showed high safe-
ty profile and lack of significant side effects [47, 52].
Saccharomyces boulardii is a probiotic that was 
shown to decrease the infection recurrence in patients 
with severe or recurring CDI [53, 54]. Studies on animal 
models showed that this probiotic causes an increase in 
antibodies against toxin A, which subsequently decreas-
es the intensity of CDI symptoms. Moreover, S. boular-
dii has an anti-inflammatory effect due to suppression 
of the nuclear transcription factor kB (NF-kB), and it 
reduces IL-8 production, which is a mediator of inflam-
matory response in CDI [55].
Products containing S. boulardii are available on the 
Polish market; some of them contain S. boulardii exclu-
sively, others contain additional probiotics and prebiot-
ics (e.g. inulin).
Clinical studies also assessed the efficacy of Lac-
tobacillus acidophilus and Bifidobacterium bifidum in 
patients receiving antibiotics in CDI prevention. The 
proportion of CDI patients was higher in the group of 
patients receiving placebo compared to those on pro-
biotic supplementation. On the other hand, patients 
receiving the probiotic were characterised by more fre-
quent C. difficile colonisation without toxin presence in 
stool [56].
Probiotics may be useful in CDI prevention if they 
are administered (without previous history of CDI) 
during antibiotic therapy [57, 58]. There have also been 
reports on infection caused by probiotic microorganisms 
[58]. Previous scientific reports showed limited success 
in CDI decrease in high-risk patients who received sys-
temic antibiotics. Due to a lack of reliable studies and 
insufficient data, there are no recommendations for 
probiotic administration in CDI prevention [51]. 
5. Treatment
5.1. Recommendation 28
Supportive treatment in CDI
The antibiotic that triggered the infection should be 
discontinued as soon as possible because it may af-
fect the risk of CDI recurrence. 
(Recommendation: strong; quality of evidence: 
moderate)
Voting:
A – 83.3%; B – 16.7%; C – 0%; D – 0%; E – 0%.
Acceptance level: hIGh.
Empirical CDI antibiotic therapy should be imple-
mented when a significant delay in laboratory con-
firmation is expected or in the case of fulminant CDI.
(Recommendation: weak; quality of evidence: low)
Voting:
A – 33.3%; B – 66.7%; C – 0%; D – 0%; E – 0%.
Acceptance level: hIGh.
5.1.1. Discussion 
Discussion is described in Recommendation 30.
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5.2. Recommendation 29
The safest and most effective treatment regimen 
for the first CDI episode
Treatment of the first CDI episode should have high 
efficacy and cause symptom relief and resolution 
within a month after the therapy. Vancomycin or  
fidaxomicin are the drugs of choice for the treatment 
of the first CDI episode. Vancomycin 125 mg four 
times a day PO for 10 days or fidaxomicin 200 mg 
twice daily for 10 days are recommended.
(Recommendation: strong; quality of evidence: high)
Voting:
A – 100%; B – 0%; C – 0%; D – 0%; E – 0%.
Acceptance level: hIGh.
Metronidazole should only be used for the first 
episode of non-severe CDI, and only in the face of 
limited access to vancomycin and fidaxomicin. The 
metronidazole regimen is 500 mg three times a day 
PO for 10 days.
(Recommendation: weak; quality of evidence: high)
Voting:
A – 83.3%; B – 16.7%; C – 0%; D – 0%; E – 0%.
Acceptance level: hIGh.
Due to potential neurotoxicity of metronidazole, 
treatment exceeding 10 days should be avoided.
(Recommendation: strong; quality of evidence: 
moderate)
Voting:
A – 100%; B – 0%; C – 0%; D – 0%; E – 0%.
Acceptance level: hIGh.
Table IX. Treatment of C. difficile infection in adults according to IDSA and SHEA guidelines [10]
Type of infection Additional information Recommended treatment
First episode with 
mild or moderate 
course
Leukocytosis ≤ 15,000/ml, 
creatinine ≤ 1.5 mg/dl
Vancomycin 125 mg PO four times a day for 10 days, or
fidaxomicin 200 mg twice daily for 10 days;
when the above are unavailable: metronidazole 500 mg PO three times 
daily for 10 days
First episode with 
severe course
Leukocytosis > 15 000/ml, 
creatinine ≥ 1.5 mg/dl
Vancomycin 125 mg PO four times a day for 10 days or
fidaxomicin 200 mg twice daily for 10 days
First episode with 
fulminant course
Shock, ileus, toxic megacolon Vancomycin 500 mg four times a day PO or through a NG tube, if ileus – 
consider adding vancomycin rectally
Metronidazole 500 mg IV every 8 h should be given together with 
vancomycin, especially if ileus is present
First relapse If the first episode was treated with metronidazole: vancomycin 125 mg PO 
four times a day for 10 days;
if the first episode was treated with standard-dose vancomycin:
vancomycin – prolonged treatment with gradually reduced doses: 125 mg 
four times a day for 10–14 days, then twice daily for a week, then once 
a day for a week, finally every 2 to 3 days for 2 to 8 weeks,
or
fidaxomicin 200 mg twice daily for 10 days
Second or 
subsequent relapse
Vancomycin – prolonged treatment with gradually reduced doses as 
described above,
or
vancomycin 125 mg four times a day for 10 days followed by rifaximin α  
400 mg three times a day for 20 days,
or fidaxomicin 200 mg twice daily for 10 days,
or
faecal microbiota transplant
5.2.1. Discussion
Treatment of the first episode of CDI involves van-
comycin orally at the dose of 125 mg four times a day 
or fidaxomicin 200 mg twice daily. The therapy should 
last for 10 days. If vancomycin or fidaxomicin is not 
available and the infection is mild, you can give met-
ronidazole 500 mg three times a day PO for 10 days. 
Prolonged metronidazole therapy can be dangerous be-
cause of its neurotoxic effect. Treatment regimens and 
comparison of treatment efficacy of the first episode 
are presented in Tables IX and X [10, 16, 59–64].
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5.3. Recommendation 30
The best management of fulminant CDI
Fulminant CDI is defined as a severe, complicated 
disease characterised by hypotension or shock, ile-
us, or acute toxic megacolon. Vancomycin PO is the 
treatment of choice for fulminant CDI. The vancomy-
cin dosage is 500 mg PO four times a day.
(Recommendation: strong; quality of evidence: 
moderate)
Voting:
A – 100%; B – 0%; C – 0%; D – 0%; E – 0%.
Acceptance level: hIGh.
When CDI is complicated by ileus, vancomycin can be 
administered rectally. The dose of vancomycin is 500 mg  
in 100 ml saline every 6 h as a retention enema.
(Recommendation: weak; quality of evidence: low)
Voting:
A – 83.3%; B – 16.7%; C – 0%; D – 0%; E – 0%.
Acceptance level: hIGh.
Metronidazole should be administered intravenously 
together with oral or rectal vancomycin, especially 
if there is intestinal obstruction. The metronidazole 
dose is 500 mg IV every 8 h.
(Recommendation: strong; quality of evidence: 
moderate)
Voting:
A – 83.3%; B – 0%; C – 16.7%; D – 0%; E – 0%.
Acceptance level: hIGh.
5.3.1. Discussion
Fulminant infection complicated by toxic mega-
colon, ileus, or shock should be treated with vanco-
mycin 500 mg PO four times daily. If intestinal ob-
struction is present, vancomycin can be administered 
rectally at the dose of 500 mg in 100 ml 0.9% NaCl 
every 6 h. Vancomycin therapy should be enhanced 
by intravenous metronidazole 500 mg three times 
daily.
Table X. Efficacy comparison of various regimens/treatment option for C. difficile infection according to IDSA and 
SHEA guidelines [10]
Evaluated outcome number of 
participants
(number of studies)
Patient 
percentage
Relative risk 
(95% CI)
P-value Quality of 
evidence
first author 
[References]
Direct comparison of metronidazole with vancomycin
Resolution of diarrhoea after  
10 days of treatment
RCT before 2000:
156 (2)
95 (MTR)
98 (VAN)
RR: 0.97 
(0.91–1.03)
0.4 Teasley [59]
Wenisch [60]
RCT before 2000:
687 (3)
75 (MTR)
85 (VAN)
RR: 0.89
(0.82–0.96)
0.002 Zar [11]
Johnson [61]
Overall RCT: 
843 (5)
78 (MTR)
87 (VAN)
RR: 0.89
(0.85–0.96)
0.0008 High
Resolution of diarrhoea after 
treatment without CDI relapse 
within a month
RCT before 2000:
156 (2)
85 (MTR)
84 (VAN)
RR: 1.0
(0.9–1.2)
1.0 Teasley [59]
Wenisch [60]
RCT after 2000: 
687 (3)
59 (MTR)
70 (VAN)
RR: 0.84
(0.74–0.94)
0.002 Zar [11]
Johnson [61]
Overall RCT: 
843 (5)
63 (MTR)
73 (VAN)
RR: 0.87 
(0.79–0.96)
0.003 High
Direct comparison of vancomycin and fidaxomicin
Resolution of diarrhoea after  
10 days of treatment
1105 (2) 88 (FDX)
86 (VAN)
RR: 1.0 
(0.98–1.1)
0.36 High Louie [62]
Cornely [63]
Resolution of diarrhoea after 
treatment without CDI relapse 
within a month
1105 (2) 71 (FDX)
57 (VAN)
RR: 1.2  
(1.1–1.4)
< 0.0001 High Louie [62]
Cornely [63]
Direct comparison of faecal transplant and vancomycin
Resolution of diarrhoea after 
treatment without CDI relapse 
by 56 days after treatment
29 (1) 81 (FMT)
31 (VAN)
RR: 2.6
(1.1–6.2)
0.01 Moderate van Nood [64]
RCT – randomised controlled trial, RR – relative risk, CI – confidence interval, MTR – metronidazole, VAN – vancomycin, FDX – fidaxomicin, FMT – faecal 
microbiota transplant. RR was calculated relative to vancomycin, i.e. RR < 1 favours vancomycin, RR > 1 favours the other treatment option compared to 
vancomycin.
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5.4. Recommendation 31
Surgical treatment for CDI
We recommend surgical treatment for critically ill pa-
tients. The preferred method is subtotal rectal-spar-
ing colectomy.
(Recommendation: strong; quality of evidence: 
moderate)
Voting:
A – 66.7%; B – 33.3%; C – 0%; D – 0%; E – 0%.
Acceptance level: hIGh.
Loop ileostomy with colonic lavage followed by van-
comycin lavage is an alternative approach that may 
lead to better treatment outcomes.
(Recommendation: weak; quality of evidence: low)
Voting:
A – 50%; B – 33.3%; C – 16.7%; D – 0%; E – 0%.
Acceptance level: hIGh.
5.4.1. Discussion
If medical treatment proves ineffective, surgical 
treatment should be considered, including subtotal 
rectal-sparing colectomy [65].
5.5. Recommendation 32
The most effective and safe treatment regimen for 
the first CDI recurrence
For the first CDI relapse, prolonged oral vancomycin 
therapy is recommended with a gradually reduced 
and pulsatile regimen instead of a second 10-day van-
comycin cycle. The dose is 125 mg four times a day 
for 10–14 days, later reduced to two times a day for 
a week, then once a day for a week, and finally once 
every two or three days for 2 to 8 weeks.
(Recommendation: weak; quality of evidence: low)
Voting:
A – 83.3%; B – 0%; C – 16.7%; D – 0%; E – 0%.
Acceptance level: hIGh.
Alternatively, the first CDI relapse can be treated with 
fidaxomicin for 10 days instead of the standard 10-
day vancomycin regimen if vancomycin was used in 
the initial therapy.
(Recommendation: weak; quality of evidence: mod-
erate)
Voting:
A – 83.3%; B – 0%; C – 16.7%; D – 0%; E – 0%.
Acceptance level: hIGh.
Vancomycin in the standard 10-day regimen should 
be given when metronidazole was used for treat-
ment of the first episode of CDI. Metronidazole treat-
ment should not be repeated.
(Recommendation: weak; quality of evidence: low) 
Voting:
A – 83.3%; B – 0%; C – 16.7%; D – 0%; E – 0%.
Acceptance level: hIGh.
5.6. Recommendation 33
The most effective and safe treatment regimen of 
the second or subsequent CDI recurrence
Patients with a second or subsequent CDI relapse 
should be treated with oral vancomycin in a pulsa-
tile regimen. The dose of vancomycin is 125 mg PO 
four times a day for 10–14 days, two times a day for 
a week, once a day for a week, then once every two 
or three days for 2 to 8 weeks.
(Recommendation: weak; quality of evidence: low)
Voting:
A – 83.3%; B – 0%; C – 16.7%; D – 0%; E – 0%.
Acceptance level: hIGh.
OR
Patients with a second or subsequent CDI relapse 
should be treated with the standard vancomycin 
oral regimen, i.e. 125 mg four times daily followed by  
400 mg rifaximin PO three times daily for 20 days.
(Recommendation: weak; quality of evidence: low)
Voting:
A – 50%; B – 33.3%; C – 16.7%; D – 0%; E – 0%.
Acceptance level: hIGh.
Alternatively, patients with a second or subsequent 
relapse of CDI may be treated orally with fidaxomicin 
200 mg twice daily for 10 days.
(Recommendation: weak; quality of evidence: low)
Voting:
A – 66.6%; B – 16.7%; C – 16.7%; D – 0%; E – 0%.
Acceptance level: hIGh.
5.6.1. Discussion
For treatment of CDI relapses, prolonged use of van-
comycin in gradually reduced doses is recommended. 
The preferred regimen is 125 mg four times a day for 
10–14 days, then 125 mg twice daily, then 125 mg once 
a day, and 125 mg every 2 to 3 days for 2 to 8 weeks. It is 
also justified to treat relapses with fidaxomicin 200 mg 
twice daily for 10 days instead of vancomycin. The van-
comycin standard 10-day regimen should be used if the 
first episode was treated with metronidazole [1].
Subsequent relapses (second or later) require pro-
longed vancomycin or fidaxomicin course. Vancomycin 
125 mg four times a day for 10–14 days, then twice 
a day for 7 days, then once a day for 7 days, then once 
a day every 2 to 3 days for a period of 2 to 8 weeks. It 
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is also possible to prescribe rifaximin α 400 mg three 
times a day for 20 days after a standard 10-day van-
comycin course. Fidaxomicin is recommended for a re-
lapse at a dose of 200 mg twice a day for 10 days.
Rifaximin αtherapy is new and was first introduced 
in the guidelines for CDI treatment in 2018. In the study 
by Garey et al. in 2011, it was shown that the use of 
rifaximin reduced the CDI recurrence significantly more 
often [66]. Treatment regimens and comparison of 
treatment efficacy for the first episode are presented 
in Tables IX and X.
5.7. Recommendation 34 
faecal microbiota transplant for CDI treatment
Faecal microbiota transplant is recommended for CDI 
treatment in patients with multiple recurrences, in 
whom targeted antibiotic therapy proved ineffective.
(Recommendation: strong; quality of evidence: 
moderate)
Voting:
A – 50%; B – 50%; C – 0%; D – 0%; E – 0%.
Acceptance level: hIGh.
5.7.1. Discussion
Antibiotic therapy used in CDI patients is associat-
ed with the risk of relapse. Some patients experience 
multiple relapses. Promising treatment outcomes in 
those cases have been obtained following faecal mi-
crobiota transplant (FMT). FMT involves administra-
tion of faecal filtrate obtained from a healthy donor 
to the patient’s intestines, with the aim of curing CDI 
and restoring the missing components of the intestinal 
microbiota. The effect can be observed after admin-
istration of one or two doses through a colonoscope 
or by rectal infusion. Curative factors in FMT therapy 
include not only live bacteria, but also bacterial com-
ponents, antimicrobial compounds of bacterial origin, 
e.g. bacteriocins or bacteriophages, which contribute 
to normalisation of intestinal microbiota after CDI. 
FMT can be administered by rectal enema, through an 
NG tube, or in the form of freeze-dried capsules. The 
capsules can potentially become popular due to their 
low invasiveness and simple administration. Patients 
undergoing FMT achieve remission of the CDI-related 
diarrhoea, which is not always the result of reinfec-
tion but can stem from post-infectious irritable bowel 
syndrome. Such postinfectious diarrhoea is associated 
with other microbiota abnormalities. The use of FMT 
can be extended to dysbiosis caused by other bacteria 
responsible for enteritis [67].
The effectiveness of FMT is still subject to research, 
and the effectiveness of FMT was lower in magnitude 
in randomised controlled trials compared to non-ran-
domised studies [68, 69]. Because the use of FMT is 
still new, the long-term effects of FMT therapy are not 
yet known.
FMT is an effective treatment option in infections 
caused by the highly virulent 027 C. difficile ribotype, 
which is also highly resistant to antibiotics. The treat-
ment consists of vancomycin for four days at the dose 
of 4 × 125 mg PO followed by FMT [70].
Donor preparation for FMT involves taking thor-
ough medical history, obtaining blood samples, testing 
for hepatitis A, B, and C viruses, and HIV infection. Col-
lected faecal samples are examined for the presence 
of parasites, toxins A and B of C. difficile, Helicobacter 
pylori antigen, and bacteria including Salmonella, Shi-
gella, Campylobacter, Escherichia coli 0157:H7, as well 
as Yersinia enterocolitica. In addition, the tests for cy-
tomegalovirus, Epstein-Barr virus, and rotaviruses are 
carried out [71].
Quraishi et al. in their meta-analysis of 37 stud-
ies, including seven randomised controlled studies, 
showed that FMT was more effective than vancomycin 
treatment (RR = 0.23, 95% CI: 0.07–0.80) for relaps-
ing and refractory CDI. The clinical effect in all studies 
was 92% (95% CI: 89–94%). Significantly higher effi-
cacy was observed if FMT was performed in the lower 
gastrointestinal tract compared to the upper segment 
– 95% (95% CI: 92–97%) vs. 88% (95% CI: 82–94%), 
p = 0.02. There were no differences between fresh and 
frozen FMT 92% (95% CI: 89–95%) vs. 93% (95% CI: 
87–97%), respectively, p = 0.84. Subsequent admin-
istration of FMT cycles after failure of the first FMT 
resulted in a further increase in treatment efficacy. Do-
nor testing was consistent, but there was variability 
in recipient preparation and FMT volume. The above 
analysis proves that FMT, regardless of the route of 
administration, is an effective treatment for recurrent 
and refractory CDI [72].
Similarly, in Poland Grzesiowski et al. [73] obtained 
the curative rate of 55/62 (88.7%) in recurrent CDI 
(rCDI); 76.5% of cures occurred after the first course 
of treatment, 14.5% after the second, and the remain-
ing 9% after the third infusion through the nasogastric 
tube. The results by Grzesiowski are particularly im-
portant because they indicate that in most cases CDI 
treatment should be planned with implementation of 
FMT cycles (not just a single transplant), bringing the 
expected curative rate to nearly 100%.
Research on faecal filtrate transfer (FFT) is under-
way. FFT is a clear brown liquid with no intense odour. 
Preparation of FFT consists of filtering faecal suspen-
sion through air pressure filtration systems; however, 
such filtrate has a reduced microbiota composition 
compared to FMT [67].
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5.8. Recommendation 35
Treatment of patients requiring continuation of tar-
geted antibiotic therapy against primary infection 
or repeated antibiotic therapy shortly after finish-
ing CDI treatment
There are currently insufficient data on patients re-
quiring continuous antibiotic therapy for the prima-
ry infection or requiring repeated antibiotic therapy 
shortly after discontinuing CDI treatment to recom-
mend prolongation of treatment against C. difficile, 
or treatment using non-standard therapy, or resum-
ing C. difficile treatment.
(not recommended)
Voting:
A – 33.3%; B – 50%; C – 16.7%; D – 0%; E – 0%.
Acceptance level: hIGh.
5.8.1. Discussion
A new form of CDI treatment is the administration 
of bezlotoxumab. It is a human monoclonal antibody 
that binds to C. difficile toxin B, neutralises it, and pre-
vents damage to the cells of the colonic mucosa. To 
date, too few studies have been conducted to confirm 
its effectiveness, and phase III trials are ongoing [74]. 
According to the data from the summary of product 
characteristics, the drug should be administered during 
antibiotic therapy for CDI [75]. The novel mechanism 
of action of the drug does not directly affect the colon 
microbiome, and bezlotoxumab therapy may be an al-
ternative treatment for recurrent C. difficile infection in 
patients at risk [76].
Research on C. difficile vaccine are still ongoing. Ac-
tive vaccination may be, in the future, a form of CDI 
prevention. There are currently three products in the 
clinical phase trials [77]. In addition, they are also being 
studied with biotherapeutics, i.e. products containing 
toxin-non-forming C. difficile strains. There is also an 
oral b-lactamase (SYN-004) being studied that is sup-
posed to protect the colonic microbiota by reducing 
the antibiotic concentration in the intestinal lumen. 
SYN-004 – ribaxamase is an oral b-lactamase that has 
been designed for administration together with intra-
venous b-lactam antibiotics [78].
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